Severe respiratory depression and sedation with transdermal fentanyl: four case studies

  title={Severe respiratory depression and sedation with transdermal fentanyl: four case studies},
  author={Claud Regnard and Anne Pelham},
  journal={Palliative Medicine},
  pages={714 - 716}
We have seen four patients with advanced cancer on transdermal (TD) fentanyl (Durogesic) develop delayed and severe respiratory depression. These cases occurred within a two-year period; three in a 15-bed specialist palliative care unit and the fourth in a nearby teaching hospital. The four cases are of concern since past and recent studies have suggested that respiratory depression with TD fentanyl is uncommon and mild. ,2 

Tables from this paper

Utilisation of transdermal fentanyl in Germany from 2004 to 2006
The aim of this study was to characterise utilisation of transdermal fentanyl in Germany and to minimise the risk of severe opioid side effects.
Toxic leukoencephalopathy due to transdermal fentanyl overdose.
A case of a 19-month-old girl who presented in coma and who was later found to have a fentanyl patch adhered to her back is reported, finding her to have changes on brain magnetic resonance imaging consistent with a toxic spongiform leukoencephalopathy.
Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit
In the experience the long action of the patch can be a disadvantage during the last days and weeks of life, due to the difficulty of dose adjustment and the risk for toxicity.
Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence
Whether or not the situation of an advanced-stage patient under palliative care and the use of opioids are risk factors for respiratory depression and their safe use in end-stage patients is determined.
The fentanyl story.
  • T. Stanley
  • Medicine
    The journal of pain : official journal of the American Pain Society
  • 2014
Bioequivalence Criteria for Transdermal Fentanyl Generics
Evidence is not sufficient to advise other bioequivalence criteria than those previously applied to transdermal fentanyl, and experimental or clinical evidence is required to provide the necessary database for final judgement of bioequivalent limits of fentanyl generics.
Use of naloxone for reversal of life-threatening opioid toxicity in cancer-related pain
The pre-hospital setting is reviewed and the need for protocols that not only take the patient’s symptoms into account, but also the patient's cancer history is identified, which should be developed by a multi-disciplinary team.
Pharmacovigilance: a review of opioid-induced respiratory depression in chronic pain patients.
In spite of the factors identified in this cases series, OIRD remains unpredictable and safe opioid prescribing requires careful titration of opioid dosages and continuous monitoring to prevent life-threatening OIRD.
Opioid-induced respiratory effects: new data on buprenorphine
  • A. Dahan
  • Medicine, Biology
    Palliative medicine
  • 2006
Buprenorphine is more favourable compared with fentanyl in respect to ventilatory control, while fentanyl causes dose-dependent respiratory depression with apnoea at high dose levels, and reversal is possible with a sufficient and continuous infusion of naloxone.
Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone)
The criteria for selecting analgesics for pain treatment in the elderly include, but are not limited to, overall efficacy, overall side‐effect profile, onset of action, drug interactions, abuse potential, and practical issues, such as cost and availability of the drug, as well as the severity and type of pain.


Inefficacy of high‐dose transdermal fentanyl in a patient with neuropathic pain a case report
The case of a 58‐year‐old female with neuropathic pain using increasing transdermal fentanyl dosages to a maximum dose of 3400 μg/h resulting in fentanyl plasma levels of 173 ng/ml is described.
Respiratory changes during treatment of postoperative pain with high dose transdermal fentanyl
This study made a longterm (72 hours) evaluation of the efficacy and possible side‐effects of transdermal delivery of fentanyl (TTS‐system) for post‐operative pain relief.
Transdermal fentanyl against postoperative pain.
60 patients (ASA class I-II) undergoing knee arthrotomy received in a double blind fashion, a transdermal drug delivery system, containing either fentanyl (delivery rate of 75 micrograms/hour)--Fentanyl TTS--or placebo, with no statistical significant difference between both groups (fentanyl or placebo).
Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients
Transdermal fentanyl can be recommended for treatment of moderate to severe cancer pain and probably may even be used as a first-line drug on step 3 of the World Health Organization recommendations in selected patient groups.
Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket.
IMPLICATIONS This case describes the narcotic overdose associated with the use of a fentanyl transdermal patch in a patient being rewarmed with an external warming blanket during surgery. The
A double-blind, placebo-controlled trial of transdermal fentanyl after abdominal hysterectomy. Analgesic, respiratory, and pharmacokinetic effects.
BackgroundA randomized, double-blind, placebo-controlled trial was conducted to assess the analgesic, pharmacokinetic, and clinical respiratory effects of 72-h application of two transdermal fentanyl
Biphasic Respiratory Depression after Fentanyl—Droperidol or Fentanyl Alone Used to Supplement Nitrous Oxide Anesthesia
Either fentanyl or Innovar was administered to supplement nitrous oxide anesthesia for operations on 29 patients, and full recovery appeared to be more rapid with Innovar than with fentanyl alone.
A Double‐blind, Placebo‐controlled Trial of Transdermal Fentanyl after Abdominal Hysterectomy Analgesic, Respiratory, and Pharmacokinetic Effects
Application of TTSF patches 2 h preoperatively is associated with moderate supplementary opioid requirements for analgesia in the early postoperative period and ongoing opioid supplementation for at least 72 h and a high incidence of respiratory depression requiring intensive monitoring, oxygen supplementation, and removal of the T TSF patches.